People channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

Subscribe to Endpoints News
Frank Zhang (Imaginechina via AP Images)

Two years af­ter step­ping down amidst house ar­rest, Frank Zhang is back as Leg­end chair

Nearly two years after his arrest as part of a smuggling investigation, Frank Zhang is back in the game.

Zhang, the founder and former CEO of GenScript Biotech, has been appointed as a director of Legend Biotech, GenScript’s CAR-T subsidiary, which he founded in 2014. He previously served as its CEO but decided to step down from the role during the ongoing investigation. Charges against Zhang were dropped earlier this year, and he had previously returned to a non-executive director role at GenScript.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

David Hallal (L) and George Daley (Hallal photo: Bertrand Guay/AFP via Getty Images)

David Hal­lal's El­e­vate­Bio launch­es new com­pa­ny to 'dis­rup­t' off-the-shelf cell ther­a­py, but pro­vides few oth­er de­tails

David Hallal’s ElevateBio is launching a new company Thursday as it looks to continue making its mark in the cell and gene therapy spaces. But Hallal is also keeping his cards close to the vest, preferring to toe the line between bombast and mystique rather than going all-in in one direction.

The new company comes out of a partnership with Boston Children’s Hospital and research from George Daley, the dean of Harvard Medical School. The triumvirate claims to have found a way to design better off-the-shelf cell therapies using new methods discovered in Daley’s Boston Children’s Hospital lab (Harvard is not involved in the collaboration).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.

Niall Condon, Curia Global's new president of the manufacturing division

Cu­ria nets con­tract for cannabi­noid can­di­date and taps a new pres­i­dent of man­u­fac­tur­ing

The CDMO Curia, fresh off an expansion a year ago, is scaling up manufacturing for a candidate from an Australian biotech.

Incannex Healthcare, a biotech centered on producing cannabinoid-based medicines and psychedelic therapies, is using Curia Global to further develop and manufacture a GMP-grade inhaled drug product for the treatment of concussion and traumatic brain injury originally developed by the biotech.

Per Norlén, incoming Evaxion Biotech CEO (via Targinta)

CEO of Dan­ish im­munother­a­py start­up hits the ex­it in the lat­est C-suite shake­up

Evaxion Biotech, a Danish startup that uses AI to develop personalized immuno-oncology therapies, is shaking up its C-suite.

Lars Staal Wegner has decided to exit as the company’s CEO, Evaxion announced Tuesday, but will remain in an advisory role to the new CEO and board of directors. Per Norlén, who has over 20 years in the industry, will take over as the new CEO in six months.

Previously, Norlén was the CEO of Targinta and CMO of Xintela.

Illustration: Henry Smith for Endpoints News

An MIT pro­fes­sor's rare dis­ease quest rip­ples through­out biotech

A decade ago, Andrew Lo desperately sought out a therapy for his mother’s lung cancer that had developed resistance to existing drugs.

As part of the quest, he met with two biotech executives. Lo, a finance professor at Massachusetts Institute of Technology, casually asked over lunch if funding influenced which drug programs the company prioritized. The company’s chief scientific officer shook his head, looking at the other executive and then Lo.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Hung, Nuvation Bio president and CEO (website via Vimeo)

David Hung's Nu­va­tion Bio ax­es clin­i­cal pro­gram, lays off 30 af­ter re­searchers say they can't man­age the side ef­fects

The latest biotech to sound the alarm comes from a David Hung startup, and it comes a little over a month after receiving a series of FDA holds.

Nuvation Bio announced Monday it would discontinue development on one of its early-stage clinical programs after regulators halted a handful of studies in late June. On top of this, Nuvation plans to lay off 30 employees, representing about 35% of its workforce, according to an SEC filing.

Laurie Glimcher, Dana-Farber president and CEO (Franck Fife/AFP via Getty Images)

Dana-Far­ber CEO Lau­rie Glim­ch­er re­signs from GSK board — is she the next NIH di­rec­tor nom­i­nee?

GSK announced this morning in a London Stock Exchange filing that Laurie Glimcher, president and CEO of the Dana-Farber Cancer Institute, has advised the company of her intention to retire from its board of directors on Oct. 13.

The company did not disclose why Glimcher has decided to move on now after more than five years as a non-executive director, but Glimcher’s appointment heralded a much bigger interest in oncology at GSK, and she’s moving on now as GSK’s R&D chief Hal Barron also hits the exit.

Small Penn­syl­va­nia biotech lays off a fourth of its staff as it tries to nav­i­gate com­mer­cial land­scape

Pennsylvania biotech Trevena put out word Thursday morning that it slashed 25% of its full-time staff and terminated a sales force agreement with Syneos, on top of a data readout it touted as positive.

The biotech’s only approved product, marketed as Olinvyk, was OK’ed back in 2020 for moderate to severe acute pain. The opioid was originally spurned by the FDA back in 2018 after efficacy data was mixed compared to morphine at key doses and the agency wanted more safety data. Two years later, it got approved for use in a hospital setting, also getting a black box warning about addiction, abuse, respiratory depression and more.

Bob Duggan and Maky Zanganeh (Summit)

Bil­lion­aire Bob Dug­gan gets CEO help as Sum­mit tests in­vestor in­ter­est in $100M of­fer­ing

Bob Duggan is getting help in the chief executive spot. The billionaire’s title looks a little different as of Tuesday, when Summit Therapeutics COO Maky Zanganeh was promoted to co-CEO and president.

Both sit on the board of directors of the California biotech, which is in the midst of raising $100 million in a public offering to boost the company’s coffers ahead of a likely new Phase III trial for a C. difficile asset that has been through multiple hurdles in recent memory. Duggan became CEO in April 2020, and Zanganeh joined in November of that year. The two previously worked together at Duggan’s Pharmacyclics, with the executive partners architecting a $21 billion exit to AbbVie in 2015.

Druglike co-founder Martin Shkreli (AP Photo/Susan Walsh, File)

Life­time phar­ma ban? ‘Phar­ma Bro’ re­turns with ‘soft­ware’ com­pa­ny for drug dis­cov­ery

Famous for skyrocketing the price of a lifesaving drug and getting into feuds with anybody and everybody on the internet and in Congress, the “Pharma Bro” is back, sort of. Instead of hiking drug prices, he claims he’s lowering the costs for those attempting to discover drugs.

Martin Shkreli has co-founded a new company, which he claims to be a “Web3 drug discovery software platform.”

That is, of course, because Shkreli received a lifetime ban from the pharmaceutical industry, a barrier that he has, as his own attorney, failed to get overturned. Yet the industry still fuels the focus of his online presence, with videos of him deriding the “lack of transparency” at Mark Cuban’s pharmacy company — which aims to reduce costs for patients — alongside other opinions and memes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.